|
Title: The vice chancellor of clinical research at Duke University suggests that a public relations agency ... Post by: EZ on Feb 7, 2018 The vice chancellor of clinical research at Duke University suggests that a public relations agency that ghostwrote an honest article about a defective drug would lose its pharmaceutical client.
What should public relations practitioners do when their research reveals that a pharmaceutical client's drug may have defects? What will be an ideal response? Title: The vice chancellor of clinical research at Duke University suggests that a public relations agency ... Post by: jhncyss on Feb 7, 2018 The PRSA Code does clearly suggest that practitioners should not mislead
members of the media and the public and should reveal sponsors for causes and interests represented. Two-way symmetry suggests that the agency might encourage the client to improve the product. However, with vast amounts of money devoted to product development, the very real possibility exists that the agency-client relationship would dissolve. It might be difficult for an ethical agency to tell a client it will work on other aspects of public relations but will look the other way while the client tries to mislead the media and the public. Title: The vice chancellor of clinical research at Duke University suggests that a public relations agency ... Post by: EZ on Feb 7, 2018 Excellent response
|